- Investor Presentation - view here
- Quarterly Shareholder Update - view here
- Investment Summary - view here
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that it has commenced dosing in the phase 2 clinical trial studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis.Read full media release - pdf
Pharmaxis CEO Gary Phillips speaks to Proactive Investors following the news the Company has been cleared to progress its bone marrow cancer trial to a phase 2 dose expansion phase. It follows further positive results of data analysis from the phase 1c clinical trial of its drug PXS‐5505.
Watch the interview here.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at three dosage levels.
Assessment with Pharmaxis’ proprietary assays of the highest dose has shown inhibition of the target enzymes, LOX and LOXL2, at greater than 90% over a 24-hour period at day 7 and day 28. The trial safety committee has reviewed the results and having identified no safety signals, has cleared the study to progress to the phase 2 dose expansion phase where 24 patients will be treated at the highest dose twice a day for 6 months.Read full media release - pdf
The 2021 Annual General Meeting of Pharmaxis will be held as a virtual meeting on Wednesday, 3 November 2020 at 10:00 am (Sydney time).
The notice of meeting, explanatory statement and proxy form made available to shareholders on 1 October 2021. The notice of meeting together with a sample proxy form is available here.
The Virtual Voting Guide is available here.
The 2021 statutory annual report is available here.